Drs Gail Roboz and Courtney DiNardo discuss methods of treating older patients with acute myeloid leukemia and managing unique toxicities. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964537). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Acute Myeloid Leukemia https://emedicine.medscape.com/article/197802-overview Cytarabine https://reference.medscape.com/drug/cytosar-u-depocyt-cytarabine-342089 Mylotarg (gemtuzumab ozogamicin) https://reference.medscape.com/drug/mylotarg-gemtuzumab-1000186 A Phase 3 Trial of Azacitidine Versus a Semi-Intensive Fludarabine and Cytarabine Schedule in Older Patients With Untreated Acute Myeloid Leukemia https://pubmed.ncbi.nlm.nih.gov/33626197/ Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia https://www.nejm.org/doi/full/10.1056/NEJMoa2012971 Ferrara Criteria https://decisionpoint.medscape.com/oncology/viewarticle/928810 Hydrea https://reference.medscape.com/drug/droxia-siklos-hydroxyurea-342100 Mucositis https://emedicine.medscape.com/article/1079570-overview Azacytidine https://reference.medscape.com/drug/onureg-vidaza-azacitidine-342263 Decitabine https://reference.medscape.com/drug/dacogen-decitabine-342091 Venetoclax https://reference.medscape.com/drug/venclexta-venetoclax-1000078 Hydroxycarbamide in Combination With Azacitidine or Decitabine Is Antagonistic on DNA Methylation Inhibition https://pubmed.ncbi.nlm.nih.gov/17686055/